Drugs / 13-valent pneumococcal conjugate vaccine (13-PCV)
13-valent pneumococcal conjugate vaccine (13-PCV)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03650114 Background | Dec 2018 → Sep 2028 expected | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-valent pneumococcal conjugate vaccine (13-PCV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03650114 ↗ |
| Modality | Vaccine | “13-valent pneumococcal conjugate vaccine (13-PCV)” NCT03650114 ↗ |